Current issues of ACP Journal Club are published in Annals of Internal Medicine


Letter

MRC/BHF Heart Protection Study

PDF

ACP J Club. 2003 Mar-Apr;138:A15. doi:10.7326/ACPJC-2003-138-2-A15



Additional Information from Commentators

In our commentary on the summary of the Heart Protection Study (HPS) in the January/February 2003 issue of ACP Journal Club (1), a table germane to our discussion had to be omitted due to space constraints and was replaced with a notation referring readers to the table on the Web site. We thank the editors for allowing us to reproduce the table below.

Regarding the HPS, derivation of the corresponding NNT/year and 95% CI for prevention of CHD events gives very similar values (165, CI 130 to 230) to those for patients in the CARE and LIPID trials. Thus, in terms of CHD prevention, statin therapy appears to confer similar levels of benefit in individuals with diverse risk factors other than hypercholesterolemia.

C. R. Kumana, FRCP
University of Hong Kong
Hong Kong, China

B. M. Cheung, FRCP
University of Hong Kong
Hong Kong, China

I. J. Lauder, PhD
University of Hong Kong
Hong Kong, China


References

1. Kumana CR, Cheung BM, Lauder IJ. Commentary on “Simvastatin reduced mortality and vascular events in high-risk patients” and “Antioxidant vitamins did not reduce death, vascular events, or cancer in high-risk patients.” ACP J Club. 2003 Jan-Feb;138:2-3. [PubMed ID: 12511114] Comment on: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22 and MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:23-33.

2. Kumana CR, Cheung BM, Lauder IJ. Gauging the impact of statins using number needed to treat. JAMA. 1999;282:1899-901. [PubMed ID: 10580441]